ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-03-11. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: metastaticsubjects withbraincellstumors
  Phrases that lowered it: first dosedose ofpatient10of study
• Sponsor's past termination rate: 27.5% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 241 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 779 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 94.2% (raises risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 8872 (lowers risk) · Drug's FDA history
• Drug's FAERS reports before start: 44212 (lowers risk) · Drug's FDA history
• Disease area, dermatology: Yes (raises risk) · Disease area
• Collaborators: 1 (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer NCT05622058 · started 2023 · scored riskier than 52% of active trials terminated
• OLAParib COmbinations NCT02576444 · started 2015 · scored riskier than 86% of active trials terminated
• Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers NCT06130254 · started 2024 · scored riskier than 70% of active trials terminated
• Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer NCT04464174 · started 2020 · scored riskier than 94% of active trials completed
• Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] NCT03428607 · started 2018 · scored riskier than 38% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.